Cyclin-dependent kinase 4/6 inhibitor combined with aromatase inhibitor for neoadjuvant therapy of breast cancer

doi:10.3877/cma.j.issn.1674-0807.2019.01.012

Chinese Journal of Breast Disease(Electronic Edition) ›› 2019, Vol. 13 ›› Issue (01): 63-64. doi: 10.3877/cma.j.issn.1674-0807.2019.01.012

Special Issue: ；；；

• Case Report • Previous Articles

Cyclin-dependent kinase 4/6 inhibitor combined with aromatase inhibitor for neoadjuvant therapy of breast cancer

Zerui Qu¹, Li Bian¹, Tao Wang¹

Received:2018-09-05 Online:2019-02-01 Published:2019-02-01

Abstract

Zerui Qu, Li Bian, Tao Wang. Cyclin-dependent kinase 4/6 inhibitor combined with aromatase inhibitor for neoadjuvant therapy of breast cancer[J]. Chinese Journal of Breast Disease(Electronic Edition), 2019, 13(01): 63-64.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2019.01.012

https://zhrxbzz.cma-cmc.com.cn/EN/Y2019/V13/I01/63

Figures/Tables 2

References 8

[1]	Beaver JA, Amiri-Kordestani L, Charlab R, et al. FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer [J]. Clin Cancer Res, 2015, 21(21):4760-4766.
[2]	U．S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.03 [EB/OL]. [2018-08-05]. URL
[3]	Ogston KN, Miller ID, Payne S，et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival [J]. Breast, 2003, 12(5):320-327.
[4]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2015版)[J]. 中国癌症杂志，2015，25(9):692-754.
[5]	李建斌，江泽飞．乳腺癌从"新辅助治疗"到"术前治疗"的理念和实践[J]. 临床外科杂志，2016，24(1):14-17.
[6]	Echavarria I, Jerez Y, Martin M, et al. Incorporating CDK4/6 inhibitors in the treatment of advanced luminal breast cancer[J]. Breast Care，2017，12(5):296-302.
[7]	Finn RS, Crown JP, Lang I，et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study [J]. Lancet Oncol，2015，16(1):25-35.
[8]	Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer [J]. N Engl J Med，2016，375(20):1925-1936.

用药	病灶大小
用药	查体	超声	MRI
治疗前	未触及	1.1 cm×0.9 cm	1.5 cm×1.4 cm
白蛋白紫杉醇1个周期	未触及	0.9 cm×0.8 cm	未做
白蛋白紫杉醇2个周期	未触及	0.9 cm×0.8 cm	1.5 cm×1.4 cm
来曲唑联合palbociclib 1个周期	未触及	0.7 cm×0.7 cm	1.2 cm×1.0 cm
来曲唑联合palbociclib 3个周期	未触及	0.8 cm×0.8 cm	0.5 cm×0.3 cm
来曲唑联合palbociclib 5个周期	未触及	0.8 cm×0.7 cm	0.4 cm×0.3 cm

用药	病灶大小
用药	查体	超声	MRI
治疗前	未触及	1.1 cm×0.9 cm	1.5 cm×1.4 cm
白蛋白紫杉醇1个周期	未触及	0.9 cm×0.8 cm	未做
白蛋白紫杉醇2个周期	未触及	0.9 cm×0.8 cm	1.5 cm×1.4 cm
来曲唑联合palbociclib 1个周期	未触及	0.7 cm×0.7 cm	1.2 cm×1.0 cm
来曲唑联合palbociclib 3个周期	未触及	0.8 cm×0.8 cm	0.5 cm×0.3 cm
来曲唑联合palbociclib 5个周期	未触及	0.8 cm×0.7 cm	0.4 cm×0.3 cm

Please choose a citation manager

Content to export

Cyclin-dependent kinase 4/6 inhibitor combined with aromatase inhibitor for neoadjuvant therapy of breast cancer

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 2

References 8

Related Articles 0

Recommended Articles

Metrics

Comments

模态框（Modal）标题

Please choose a citation manager

Content to export

Cyclin-dependent kinase 4/6 inhibitor combined with aromatase inhibitor for neoadjuvant therapy of breast cancer

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 2

References 8

Related Articles 0

Recommended Articles

Metrics

Comments